TheraRadar
Clinical-Stage Companies / Cutia Therapeutics（Wuxi）

Cutia Therapeutics（Wuxi）

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 9/12/2024

8
Total Trials
3
Phase 3
2
Phase 2
0
Recruiting
73
Score

Pipeline by Phase

Phase 3
3
Phase 2
2
Phase 1
4

Therapeutic Focus

AGA Glabellar Frown Lines Atopic Dermatitis Efficacy and Safety Safety

Clinical Trials (8)

NCT06585696 Phase 3 COMPLETED

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)

Started: 6/24/2024

NCT05793892 Phase 3 COMPLETED

Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults

Started: 4/6/2023

NCT05135468 Phase 3 COMPLETED

A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)

Started: 12/6/2021

NCT06194188 Phase 2 COMPLETED

A Phase 2 Clinical Study of CU-20401

Started: 12/20/2023

NCT06744569 Phase 1 ENROLLING BY INVITATION

A Phase I Clinical Trial to Evaluate CU-10101 Unguent

Started: 9/12/2024

NCT05195541 Phase 1 COMPLETED

A Clinical Study to Evaluate the Safety, Pharmacokinetic Profile and Efficacy of CU-20401

Started: 2/27/2022

NCT05173883 Phase 1 COMPLETED

A Phase 1 Clinical Study of CU-20401 in Chinese Healthy Population

Started: 12/20/2021

NCT05380427 Phase 1 COMPLETED

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects

Started: 8/15/2022

Drug Candidates

CU-20101 treatment for Moderate to Severe Glabellar Striae CU-10101 Subcutaneous injection of CU-20401 CU-20401 injection ，CU-20401 Lidocaine tetracaine cream CU-40101 CU-40102 Spray
Activity Status: Slowing
Last Trial Started: 9/12/2024
Last Trial Ended: 11/20/2025
Trials (12 months): 0
Completed Trials: 7
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.